Antonio Pagliuca

Professor of Stem Cell Transplant @KingsCollegeLon | @KingsCollegeNHS |External Medical Adviser, @AnthonyNolan | Views are my own.

[Antonio Pagliuca @ProfBMT]

@Soccer_Stats Palace 12 I believe?

[Antonio Pagliuca @ProfBMT]

@CPFC The Magician disappears after diving into the Vortex he created.
Well done Oliver. 🦅👏

[Antonio Pagliuca @ProfBMT]

@CPFC Is he the only player to win back to back FA cup medals with two different clubs?

[Antonio Pagliuca @ProfBMT]

@tobyeyre82 - what are your views on the treatment path following this decision.

[Anthony Nolan @AnthonyNolan]

We are deeply concerned at the decision by NICE to remove the CAR-T treatment Tecartus (brexu-cel) for Mantle Cell Lymphoma (MCL)  after 4 years of it being available on the NHS in England and Wales.

[Harry Spoelstra @HarrySpoelstra]

🔥This fantastic antigenic map work reveals BA.3.2 as a stark outlier among SARS-CoV-2 variants, suggesting current monovalent vaccines and prior immunity probably offer weak protection against it. 🧵👇
Thanks @Mike_Honey_ 👏

[Vincent Rajkumar @VincentRK]

The FDA has granted a National Priority Voucher to the Tec-Dara combination for myeloma. What does this mean? It’s huge!

This means Tec-Dara combo may be approved within 1-2 months. Fingers crossed. https://t.co/JIEGSVyHPb

[Samuel Hume @DrSamuelBHume]

This is an extraordinary result

Teclistamab (CD3 x BCMA bispecific antibody) plus Daratumumab (CD38 antibody) vs. standard care for relapsed or refractory multiple myeloma

The future of medicine is very very bright

[Emma M. Groarke @emmamgroarke]

Super excited we got to present the new @ASH_hematology guidelines for diagnosis and management of aplastic anemia. #ASH25 @scheinbp @AustinKulasekar

[Antibiotic Steward Bassam Ghanem ��️C🆔🅿️🌟 @ABsteward]

I get it—COVID isn’t trendy anymore but this new study is worth a look!
🆕💫Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial #IDXposts
https://t.co/sRPOkcdl8y

[Philip McCarthy @PLMcCarthyMD]

https://t.co/6YWdR6jEND

[NHS England @NHSEngland]

From 1 September, all severely immunosuppressed adults aged 18 years and over will be able to get the shingles vaccine from their GP.

The vaccine significantly reduces the chance of developing shingles – protecting thousands more people most at risk.

ℹ️ https://t.co/LpUb2zZocv

[Marc Johnson @SolidEvidence]

It’s been 2 years since BA.2.86 first appeared (and I’m give the variant update to SAVE on Monday), so I thought I would do a little summary about this era of SARS-CoV-2 evolution.
1/

[Beth Psaila @beth_psaila]

Huge thanks to @CR_UK for funding and sparking collaborations that led to this, our co-authors @MRC_WIMM @UniofOxford @Ludwig_Cancer @EdinburghUni, and all those who provided feedback and suggestions along the way @GordonConf @ASH_hematology @ISEHSociety and our editors+reviewers

[Klebanoff_Lab @KlebanoffLab]

🤯Three (!!!) new papers today in @ScienceMagazine on the application of generative AI for the de novo design of peptide/HLA binding molecules! Completely unique 3D structure and binding mode compared with natural TCRs and TCR mimics! Links to papers 👇

[Vincent Rajkumar @VincentRK]

A historic day for myeloma!!
After 5 decades of research.

European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial.

@thanosdimop @PlasmaCellPete https://t.co/S7en5nopSx

[Antonio Pagliuca @ProfBMT]

RT @PalaceReport: 🚨 "All football fans, RT this and let’s show UEFA the support from all clubs to reinstate Crystal Palace FC in the Europa…

[Dr. Chokri Ben Lamine @abouabdrahman0]

🔬 AML Classification: WHO 5th vs ICC 🩸🧵

1️⃣ WHO 5th Edition:
✅ AML with defining genetic abnormalities (no blast threshold):
•🧬 Fusion: RUNX1::RUNX1T1, CBFB::MYH11, DEK::NUP214, BCR::ABL1, etc.
•🧬 Rearrangements: KMT2A, MECOM, NUP98
•🧬 Molecular: NPM1, CEBPA

⚠️ If none:
➡️ AML defined by differentiation (blasts ≥20%):
•AML M0, M1, M2, M4, M5, M6, M7, etc.

🩺 Separate group:
•Post-cytotoxic therapy
•Germline predisposition

📄 Ref:
•WHO Classification of Haematolymphoid Tumours 5th Ed

⸻

2️⃣ ICC Classification:
✅ AML with recurrent genetic abnormalities (blasts ≥10%):
•RUNX1::RUNX1T1, CBFB::MYH11, DEK::NUP214, NPM1, BCR::ABL1, in-frame bZIP CEBPA

➡️ If no:
✅ AML with TP53 mutation (VAF >10%)
➡️ If no:
✅ AML with myelodysplasia-related gene mutation
➡️ If no:
✅ AML with myelodysplasia-related cytogenetic abnormality
➡️ If no:
✅ AML – NOS

⚠️ Appended qualifiers:
•💉 Therapy-related
•📈 Prior MDS
•📈 Prior MDS/MPN
•🧬 Germline predisposition

⚠️ Blast %:
•10–19%: MDS/AML
•≥20%: AML

📄 Ref:
•ICC 2022 Haematological Malignancies Classification

⸻

🩺 Key takeaways:
✅ ICC lowers blast threshold to 10% if recurrent genetic abnormality present.
✅ WHO retains 20% threshold unless defining genetics.
✅ Emphasis on genetics > morphology.
✅ Clear approach to therapy-related and germline AML.

⸻

🔗 Save for #Hematology #Boards
🔗 Share with your #Pathology team
🔗 Use during #AML discussions and teaching

[BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech]

1/ 🧪 The Era of In-Vivo CAR-T Has Arrived

No leukapheresis.
No lymphodepletion.
No 3-week manufacturing delay.

Just a vial and a vein.

EsoBiotech’s in-vivo BCMA CAR-T has shown deep responses in myeloma after a single infusion.

Here’s why that matters 🧵

[vittorio @IterIntellectus]

holy shit, it’s here!

deepmind just released AlphaGenome.
an AI model that reads 1 million bases of DNA and predicts how any mutation changes molecular function

not just in single genes but across the entire regulatory genome.

DNA is code, and you are software
1/

[Eric Topol @EricTopol]

Just published @ScienceMagazine
Engineering T cells within the body, a big step forward for treating cancer and autoimmune diseases, as demonstrated in animal models
https://t.co/AGt4Bxhw9e
https://t.co/a0qjSdmEAX